Trial Scout

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Study Location

Southtowns Gastroenterology

ClinicalTrials.gov Identifier: NCT03558152
Recruitment Status: Recruiting
First Posted: 6/15/2018 12:00:00 AM
Last Update Posted: 3/4/2019 12:00:00 AM

Study Description

Eligibility Criteria

Additional Contacts

Brief Summary

A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis

Condition or Disease

Colitis
Colitis, Ulcerative
Ulcer

Intervention/Treatment

Drug: Vedolizumab Placebo / The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.

Phase

Phase 2

Detailed Description

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Go to ClinicalTrials.gov >